Veenat (Imatinib)

Medicine Overview

Veenat (Imatinib) is a targeted cancer therapy designed to treat chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and other specific cancers by blocking abnormal protein activity that causes cancer cell growth. This medication works at a molecular level to slow or stop tumor progression, offering patients a highly effective and well-tolerated treatment option. Its precision-targeting mechanism helps reduce damage to healthy cells, making it a preferred choice for long-term cancer management. Veenat is ideal for patients seeking a proven oral therapy with a strong clinical track record.